BioSpace News Archive

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® blood glucose monitoring system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring Systems, announces that it has successfully completed the initial European launch of the next-generation Eversense® E3 CGM System.

Oncology Specialists of Charlotte and OneOncology, a national platform for independent oncology practices, announced that the two organizations have finalized an agreement to partner to enhance the delivery of cancer care services to communities in and around Charlotte, North Carolina.

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that the Company voluntarily withdrew its 510(K) application on October 5, 2022, for its next-generation MR IV pump.

Surrozen, Inc. today announced the presentation of data supporting the continued development of its lead therapeutic programs at United European Gastroenterology Week (UEGW), being held Oct. 8-11 in Vienna.

scPharmaceuticals Inc. today announced that the company has entered into a binding term sheet with respect to a $100 million secured debt facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).

JW Therapeutics announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for its anti-CD19 autologous chimeric antigen receptor T.

Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alzheimer’s Disease (AD) biomarker study.

Novavax, Inc. will present new safety and immunogenicity data from the first Phase 1/2 COVID-Influenza Combination (CIC) dose-finding trial evaluating its CIC vaccine candidate at the World Vaccine Congress (WVC) Europe, October 11 to 14, 2022.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).

Sudo Biosciences today announced the appointment of Imran Babar, Ph.D., as chief business officer.